Announced Wed, 8 Jul · 13:10 IST
Suven Life Sciences: WOS in Singapore, Rs 249 cr preferential issue, director re-appointment
Strategic Transactions View source PDF
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+10.2%1-day move
₹317.50
prior close
₹324.15
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.0+0.0+0.9+1.4+10.2+12.3+13.1+9.9+12.5+2.2————
Up moveDown movePending
AI summary
Board on July 8, 2026 approved three items. 1) Allotted 1.85 crore shares at Rs 134 each on warrant conversion to 17 non-promoter investors, raising Rs 248.84 crore. Paid-up capital rose to Rs 28.26 crore. 2) Re-appointed Dr. Vajja Sambasiva Rao as Independent Director for 5 years. 3) Incorporating wholly owned subsidiary Suven Neurosciences Pte. Ltd. in Singapore for neurological biotech, with USD 100 million investment.
Likely market impact
Capital raise of Rs 249 cr strengthens balance sheet; Singapore WOS signals global push in neuro biotech.